Biomea Fusion, Inc. Common Stock (BMEA) is a publicly traded Healthcare sector company. As of July 26, 2026, BMEA trades at $1.25 with a market cap of $90.37M and a P/E ratio of -1.06. BMEA moved -0.79% today. Year to date, BMEA is +0.81%; over the trailing twelve months it is -30.94%. Its 52-week range spans $0.87 to $7.46. Analyst consensus is strong buy with an average price target of $7.20. Rallies surfaces BMEA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Biomea Fusion Reports 52% C-Peptide Gain, 1.8% HbA1c Drop and BMF-650 Expansion: Biomea Fusion presented data showing icovamenib enhances GLP-1 expression, promotes muscle preservation and induces adipocyte browning. In COVALENT trials, it achieved a 52% C-peptide increase at Week 12 in T1D and a 1.8% placebo-adjusted HbA1c reduction through Week 52 while adding a rapid titration cohort to its BMF-650 study.
| Metric | Value |
|---|---|
| Price | $1.25 |
| Market Cap | $90.37M |
| P/E Ratio | -1.06 |
| EPS | $-1.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.46 |
| 52-Week Low | $0.87 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.86M |
| Net Income | $-61.80M |
| Gross Margin | 0.00% |
5 analysts cover BMEA: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.20.